Dear Editor, We read the article titled 'DNA chip-assisted diagnosis of a previously unknown etiology of intermediate uveitis-Toxoplasma gondii', by Basu et al., with great interest. [1] We appreciate their attempt to draw attention towards the superior efficacy of Polymerase Chain Reaction (PCR) as a diagnostic tool in the etiology of uveitis and take this opportunity to put forth our views.
The biggest thorn in the side in a case of uveitis (especially posterior) is the diagnosis of the specific causative agent or factor, thereafter ensuring appropriate treatment for complete resolution of the condition. Being an inflammatory condition, uveitis is most commonly seen as a sequel to a rigmarole of infectious or non-infectious pathologies. Picking out a specific etiological factor or agent is like finding needle in a haystack. The clinical evaluation here gives a direction and the ancillary laboratory investigations help in shaping the diagnosis. But sometimes, especially in cases of non-responders or relapsers we need a bull's eye diagnosis, which is provided by sophisticated modalities like PCR, presenting irrefutable evidence, therefore assisting in pinpoint diagnosis and specific treatment.
Multiplex PCR mentioned in the article by Basu et al., is one of the various modifications of PCR used to rapidly detect deletions or duplications in a large gene. By targeting multiple genes at once, it gains additional information from a single test run which otherwise would require several times the reagents and more time to perform. [1, 2] To elaborate our point, we analyze the role of PCR in the diagnosis of various conditions leading to uveitis by exemplification. Beginning with viral infections, the viral DNA or RNA can be identified by gene detection using quantitative real-time PCR in the intraocular fluid samples. [3] For parasitic protozoans like Toxoplasma, PCR testing for antibody titers in aqueous or vitreous has been proved to carry a high degree of specificity and sensitivity. PCR is also effective in identifying bacterial infections, e.g., detection of the Mycobacterium tuberculosis complex by IS6I I0 primer-based PCR. Not only does it identify the agents but also distinguishes amongst organisms belonging to the same genus. [4] To cite an example of the diagnostic capability of PCR in non-infectious conditions we take the Vogt-Koyanagi-Harada disease, in which the Interleukin-21 messenger RNA expression by peripheral blood mononuclear cells is determined by reverse transcriptase-PCR. [5] These few examples are just the tip of the iceberg of the numerous conditions in which PCR is useful.
Despite all these benefits, the major constraints in using this investigation regularly in a country like ours are cost, availability and the enormous patient load, especially in rural areas. Such an advanced investigation is available in precious few centers located in cities making it inaccessible to the masses. Adequate patient education and providing economical services to remote areas may serve as an answer to this problem.
Our experience of fibrin sealantassisted implantation of Ahmed glaucoma valve
Dear Editor, While I commend the work by Dr Nikhil and team for their innovative use of fibrin glue for scleral patch graft in Ahmed glaucoma valve implantation, [1] I have a few queries and comments. 1. The size of the graft stated to have been used was 4-5 mm.
I wonder if this size would suffice to achieve a good seal of the patch graft over the tube with fibrin glue as there would be less flat surface for good apposition. A larger graft can overcome this. Scleral patch graft is thicker than Tutoplast used by Kahook and Noecker [2] and one can This is only yet another indication for use of fibrin blue. In the Indian context, use of glue does not give any added advantage but in contrast, only increases the cost of surgery given the fact that implants are expensive. If one plans to use fibrin sealant then it should be utilized for conjunctival closure as well.
The outer diameter of the drainage tube of the Ahmed glaucoma valve (AGV) is 0.63mm. [2] Therefore, the width of the patch graft on either side of the tube is about 2mm. We could achieve good adhesion of the scleral patch graft by gently stroking it over the underlying tube and host sclera with a muscle hook after applying the components of the fibrin sealant between the surfaces. One may use a partial thickness scleral graft if the thickness of the latter is thought to be more or use a wider graft if so required.
Tube cornea touch and conjunctival erosion are related to the placement of the patch graft. [3] Posterior retraction of the scleral patch graft did occur in one eye. The complication is discussed in our article. [1] As the fibrin sealant is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, despite viral inactivation techniques and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. While no ocular infection has been attributed to the use of fibrin sealant, transmission of systemic parvovirus B19 infection by fibrin sealant has been reported. [4, 5] None of our patients had infection related to the use of the fibrin sealant.
Conjunctival closure by fibrin sealant requires mobile conjunctiva to limit post-operative retraction, which can overcome the tensile strength of the fibrin sealant, [6] especially with the movement of eyelids. Most of our patients had undergone at least one conjunctival manipulating surgery with resultant significant conjunctival fibrosis. Therefore, we did not use fibrin sealant to close the conjunctival wound during AGV implantation.
The implant drainage tube or the base plate may erode into the globe through the underlying thinned host sclera in staphylomatous eyes. We do staphyloma repair, when indicated prior to implantation of AGV in intractable glaucoma.
The fibrin sealant can be prepared side by side by an assistant as the surgery is being performed. The globe is hypotonous when the anchoring sutures to the scleral patch graft are taken and a safe suturing may be time consuming. We therefore, felt that the fibrin sealant-assisted placement of the scleral patch graft may reduce the overall surgical time. We do agree on the issue of increase in the cost of AGV implantation with the use of fibrin sealant. Nevertheless, we have suggested measures to reduce the per-patient-price of the fibrin sealant in the article.
